Cargando…
Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090627/ https://www.ncbi.nlm.nih.gov/pubmed/35181744 http://dx.doi.org/10.1038/s41409-022-01609-6 |
| _version_ | 1784704765629825024 |
|---|---|
| author | Hell, Saskia Jentzsch, Madlen Franke, Georg-Nikolaus Jäkel, Nadja Schulze, Susann Edelmann, Jeanett Nenoff, Kolja Grieb, Nora Jeremic, Veljko Cross, Michael Leiblein, Sabine Bach, Enrica Pönisch, Wolfram Al-Ali, Haifa-Kathrin Schwind, Sebastian Platzbecker, Uwe Lange, Thoralf Niederwieser, Dietger Vucinic, Vladan |
| author_facet | Hell, Saskia Jentzsch, Madlen Franke, Georg-Nikolaus Jäkel, Nadja Schulze, Susann Edelmann, Jeanett Nenoff, Kolja Grieb, Nora Jeremic, Veljko Cross, Michael Leiblein, Sabine Bach, Enrica Pönisch, Wolfram Al-Ali, Haifa-Kathrin Schwind, Sebastian Platzbecker, Uwe Lange, Thoralf Niederwieser, Dietger Vucinic, Vladan |
| author_sort | Hell, Saskia |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9090627 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90906272022-05-12 Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15 Hell, Saskia Jentzsch, Madlen Franke, Georg-Nikolaus Jäkel, Nadja Schulze, Susann Edelmann, Jeanett Nenoff, Kolja Grieb, Nora Jeremic, Veljko Cross, Michael Leiblein, Sabine Bach, Enrica Pönisch, Wolfram Al-Ali, Haifa-Kathrin Schwind, Sebastian Platzbecker, Uwe Lange, Thoralf Niederwieser, Dietger Vucinic, Vladan Bone Marrow Transplant Correspondence Nature Publishing Group UK 2022-02-18 2022 /pmc/articles/PMC9090627/ /pubmed/35181744 http://dx.doi.org/10.1038/s41409-022-01609-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correspondence Hell, Saskia Jentzsch, Madlen Franke, Georg-Nikolaus Jäkel, Nadja Schulze, Susann Edelmann, Jeanett Nenoff, Kolja Grieb, Nora Jeremic, Veljko Cross, Michael Leiblein, Sabine Bach, Enrica Pönisch, Wolfram Al-Ali, Haifa-Kathrin Schwind, Sebastian Platzbecker, Uwe Lange, Thoralf Niederwieser, Dietger Vucinic, Vladan Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15 |
| title | Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15 |
| title_full | Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15 |
| title_fullStr | Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15 |
| title_full_unstemmed | Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15 |
| title_short | Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15 |
| title_sort | prospective phase ii study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—eudract #: 2007-002420-15 |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090627/ https://www.ncbi.nlm.nih.gov/pubmed/35181744 http://dx.doi.org/10.1038/s41409-022-01609-6 |
| work_keys_str_mv | AT hellsaskia prospectivephaseiistudyofpreemptivechimerismdrivenreductionofimmunosuppressionafternonmyeloablativeconditioningeudract200700242015 AT jentzschmadlen prospectivephaseiistudyofpreemptivechimerismdrivenreductionofimmunosuppressionafternonmyeloablativeconditioningeudract200700242015 AT frankegeorgnikolaus prospectivephaseiistudyofpreemptivechimerismdrivenreductionofimmunosuppressionafternonmyeloablativeconditioningeudract200700242015 AT jakelnadja prospectivephaseiistudyofpreemptivechimerismdrivenreductionofimmunosuppressionafternonmyeloablativeconditioningeudract200700242015 AT schulzesusann prospectivephaseiistudyofpreemptivechimerismdrivenreductionofimmunosuppressionafternonmyeloablativeconditioningeudract200700242015 AT edelmannjeanett prospectivephaseiistudyofpreemptivechimerismdrivenreductionofimmunosuppressionafternonmyeloablativeconditioningeudract200700242015 AT nenoffkolja prospectivephaseiistudyofpreemptivechimerismdrivenreductionofimmunosuppressionafternonmyeloablativeconditioningeudract200700242015 AT griebnora prospectivephaseiistudyofpreemptivechimerismdrivenreductionofimmunosuppressionafternonmyeloablativeconditioningeudract200700242015 AT jeremicveljko prospectivephaseiistudyofpreemptivechimerismdrivenreductionofimmunosuppressionafternonmyeloablativeconditioningeudract200700242015 AT crossmichael prospectivephaseiistudyofpreemptivechimerismdrivenreductionofimmunosuppressionafternonmyeloablativeconditioningeudract200700242015 AT leibleinsabine prospectivephaseiistudyofpreemptivechimerismdrivenreductionofimmunosuppressionafternonmyeloablativeconditioningeudract200700242015 AT bachenrica prospectivephaseiistudyofpreemptivechimerismdrivenreductionofimmunosuppressionafternonmyeloablativeconditioningeudract200700242015 AT ponischwolfram prospectivephaseiistudyofpreemptivechimerismdrivenreductionofimmunosuppressionafternonmyeloablativeconditioningeudract200700242015 AT alalihaifakathrin prospectivephaseiistudyofpreemptivechimerismdrivenreductionofimmunosuppressionafternonmyeloablativeconditioningeudract200700242015 AT schwindsebastian prospectivephaseiistudyofpreemptivechimerismdrivenreductionofimmunosuppressionafternonmyeloablativeconditioningeudract200700242015 AT platzbeckeruwe prospectivephaseiistudyofpreemptivechimerismdrivenreductionofimmunosuppressionafternonmyeloablativeconditioningeudract200700242015 AT langethoralf prospectivephaseiistudyofpreemptivechimerismdrivenreductionofimmunosuppressionafternonmyeloablativeconditioningeudract200700242015 AT niederwieserdietger prospectivephaseiistudyofpreemptivechimerismdrivenreductionofimmunosuppressionafternonmyeloablativeconditioningeudract200700242015 AT vucinicvladan prospectivephaseiistudyofpreemptivechimerismdrivenreductionofimmunosuppressionafternonmyeloablativeconditioningeudract200700242015 |